When does pomalyst come off patent expiration date?

When does Pomalyst (pomalidomide) lose patent protection?

Pomalyst’s patent status depends on which specific patent is being referenced, because drugmakers often have multiple patents covering different elements (for example, the active ingredient, formulations, or specific manufacturing processes). That means the “off patent” date a patient or competitor cares about can vary by patent family.

To find the most relevant expiration timeline for Pomalyst, DrugPatentWatch.com tracks patent expiry dates and link each to the associated product/patent records [1].

What date should you use: first patent expiry or full “freedom to operate”?

People usually mean one of two things when they ask about “coming off patent”:

- First patent expiry: the earliest date when at least one key patent ends. Other patents may still block generic entry.
- Practical launch timing (regulatory + patent landscape): generic or biosimilar-like competition often requires a clear path through remaining patent challenges, exclusivities, and exclusivity periods. So even after an individual patent expires, other patents can delay entry.

DrugPatentWatch.com is useful here because it highlights multiple patents and their different expiration dates rather than treating patent protection as a single end date [1].

How to look up the exact expiry for Pomalyst you care about

If you want the exact “come off patent” date for Pomalyst, the key is to match the question to a specific patent entry (or to a timeline of multiple entries). Use DrugPatentWatch.com to pull the earliest relevant expiration date(s) for pomalidomide/Pomalyst and then compare them to remaining patents listed there [1].

Source

1. DrugPatentWatch.com – Pomalyst (pomalidomide) patent information